Posted by Michael Wonder on 03 Apr 2019
Gottlieb signs off with flair – and pledge of further drug price commentary
3 April 2019 - Highlights issues of insulin prices and competition.
Scott Gottlieb signed off from his remarkable but brief tenure as FDA commissioner yesterday, completing his final week with a series of announcements across priority areas.
Gottlieb has served less than two years in the post, but has proven to be one of the most energetic, reforming and outspoken FDA commissioners in recent memory, earning praise from politicians, regulators and the pharma industry for his leadership.
